outcomes and reduced the risk of primary non-function and ischemic cholangiopathy.
Despite steady growth in the use of DCD donor livers in adult practice over the past two decades, their use in the pediatric population remains very uncommon. Published reports from single-center studies suggest favorable outcomes are possible; 5, 6 however, in general, there has been reluctance to use these organs for fear of poor outcomes, such as primary non-function, biliary complications, or thrombotic events. In addition, the low frequency of DCD use has perpetuated a lack of familiarity with best practices for organ selection, risk reduction, and strategies to maximize recipient outcomes in pediatric liver transplantation.
We examined whether outcomes with DCD liver allografts in the US pediatric patient population justified the continued reluctance for their use. Patient and allograft outcomes were examined for all pediatric DCD recipients in the UNOS database.
| MATERIAL S AND ME THODS
The UNOS database was queried to identify all patients who un- 
| RE SULTS
Fifty-seven pediatric patients received a DCD liver allograft over the time period studied, representing 0.49% of the 11 646 pediatric recipients of deceased donor livers. In comparison, 4670 of 114 621 adult recipients (4.1%) received a DCD liver allograft. Of the 57 pediatric DCD allograft recipients, 54 livers were transplanted as whole organs and three were left lateral segments.
| Recipient characteristics
Pediatric DCD recipients were found to be significantly older than pediatric DBD recipients, 7.7 years vs 5.2 years, respectively. In addition, DCD recipients were also found to have a significantly higher Table 1 ). The recipients of a DCD liver were also more likely to be on mechanical or ventilatory support than DBD recipients, but less likely to have had a previous surgery than DBD recipients ( Table 2 ). The most common indication for transplantation in the DCD group was biliary atresia (21%) followed by acute hepatic necrosis (19%). In the DBD group, the two most common indications for transplantation were also biliary atresia followed by acute hepatic necrosis, but at rates of 28% and 10%, respectively. There were no significant differences between the DCD and DBD groups in terms of gender, blood type, or ethnicity. Surgical technique and use of thrombolytics were not available for analysis in the database and were not included for the study.
| Donor characteristics
Analysis of the donor characteristics for these pediatric recipients of DCD and DBD organ indicated there were no significant differences cross-clamp to reperfusion), share category, or distance to transplant center. The most likely cause of donor death in the DCD group was anoxia, while in the DBD group was head trauma (Table 1) . Given the restrictions on the data available through the database, we were unable to stratify the donors for stability prior to the time of recovery, including assessing for parameters such as use of inotropic agents, length of hospitalization, or trends in transaminases.
| Transplant outcomes
Allograft and overall patient survival of DCD to DBD allografts were compared using Kaplan-Meier survival curves and analyzed using logistic regression. There were no differences in allograft survival between the two groups ( Figure 1 , P = NS). However, patient survival in the DCD allograft group was superior to patient survival in the DBD allograft group (Figure 2 , P < 0.05).
Allograft failure was examined, and there were no differences between the two pediatric groups in terms of allograft failure from primary non-function, vascular thrombosis, biliary complication, non-compliance, acute rejection, or chronic rejection. In addition, there were also no differences between the two groups in terms of length of stay in days (26.4 days vs 28.9 days, DCD vs DBD, respectively), or rejection at 6 months or 12 months post-transplant (Table 3) . Interestingly, there were no instances of graft loss due to biliary complications found in pediatric DCD recipients.
| Comparison of dcd allografts used in pediatric and adult recipients
Analysis of practices in adult and pediatric practice demonstrated higher selectivity for favorable donor characteristics in pediatric DCD donors. As summarized in Table 4 , donor age and BMI were lower in the pediatric group; however, there was a longer cold storage time and distance to transplant center in the pediatric group.
The warm ischemic times in the two groups were not significantly different, at 16.9 minutes vs 16.4 minutes, pediatric vs adult DCD groups, respectively.
Allograft survival in pediatric recipient of DCD allografts was significantly better when compared with adult recipients of DCD allografts ( Figure 3 , P < 0.05). Similarly, pediatric recipients of a DCD allograft had a significantly better patient survival compared to adult DCD allograft recipients. Allograft failure that was attributed to diffuse cholangiopathy was noted in 161 adult recipients; however, there were no recorded instances of diffuse cholangiopathy in any pediatric recipient of DCD livers. Allograft failure as a result of vascular thrombosis or acute rejection was seen more frequently in DCD recipients (Table 5 ).
| Trends in DCD use
Finally, outcomes were examined over the four decades. In this analysis, high-volume pediatric transplant centers were defined as those centers that have performed 100 or more pediatric liver transplants in the history of the program. Based on era, the highest number of pediatric liver transplants was performed in era 3, where 33 were transplanted, and based on region, the most (Figure 4 ). In addition, high-volume pediatric transplant centers were found to perform a significantly higher number of pediatric DCD liver transplants when compared to lowvolume centers. Allograft survival showed a non-significant trend toward better outcomes in high-volume centers. In addition, the ages of both donors and recipients in these centers were younger, and there was a trend toward shorter cold storage time. Early efforts to use DCD organs in era 2 (1990-1999) did not have good outcomes; however, thereafter outcomes from DCD allografts were seen to improve with every successive era ( Figure 5 ).
| D ISCUSS I ON
DCD utilization in pediatric liver transplantation continues to be a rare event, and there is little contemporary literature to guide practice in this specific population of patients. In the present study, we have used data from the UNOS database to determine the cumulative outcomes and experiences of the US pediatric centers. Abt et Despite these differences, survival of the DCD allograft was comparable to the DBD allograft, and remarkably, the patient survival in the DCD allograft recipients was superior to DBD recipients.
When examining the causes of allograft failure, in particular, it is noteworthy that no significant differences were detected between DBD and DCD recipients with regard to primary non-function, vascular thrombosis, biliary complications, non-compliance, acute rejection, or chronic rejection. Surprisingly, there were no biliary complications in the DCD group that lead to graft failure. This remarkable finding may be compromised by under reporting, which is a weakness of large registry datasets. The absence of biliary complications, however, has also been reported in single-center studies 5 and may reflect carefully chosen DCD donors.
Pediatric recipients of DCD allografts were compared to adult recipients of DCD allografts and, as expected, were found to have superior outcomes. This is likely the combination of donor and recipient The current study is retrospective and limited by the fidelity of data entry. Despite this, it remains intriguing that outcomes in pediatric recipients who have received a DCD allograft are comparable to a DBD allograft, and that concerns of primary non-function and biliary complications seem inflated.
As such, we would suggest that DCD liver allografts are an untapped source in the pediatric patient population, and use of DCD liver allografts should be strongly considered to increase organ availability and reduce deaths on the wait list for this patient population.
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